Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026)

Enliven Therapeutics has disclosed Retained Earnings across 8 years of filings, most recently posting -$382000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$382000.0, down 2287.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$382000.0 (down 2287.5% YoY), and the FY2025 annual result was -$347.2 million, down 631310.91% from the prior year.
• Retained Earnings came in at -$382000.0 for Q1 2026 at Enliven Therapeutics, up from -$347.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $141000.0 in Q4 2023 to a low of -$347.2 million in Q4 2025.
• The 5-year median for Retained Earnings is -$114.3 million (2023), against an average of -$126.2 million.
• Peak annual rise in Retained Earnings reached 100.17% in 2023, while the deepest fall reached 3377400.0% in 2023.
• Enliven Therapeutics' Retained Earnings stood at -$82.9 million in 2022, then soared by 100.17% to $141000.0 in 2023, then plunged by 60.99% to $55000.0 in 2024, then tumbled by 631310.91% to -$347.2 million in 2025, then jumped by 99.89% to -$382000.0 in 2026.
• The last three Retained Earnings figures came in at -$382000.0 (Q1 2026), -$347.2 million (Q4 2025), and -$317.5 million (Q3 2025), per Business Quant data.